NASA picks Alabama site as headquarters for human moon lander programme: sources
By Joey Roulette WASHINGTON (Reuters) - The head of NASA is set to announce plans on Friday to name the U.S. space agency's Marshall Space Flight Center in Alabama as headquarters for its human lunar lander programme, signalling progress in its drive to put astronauts back on the moon by 2024, three people familiar with the plan said.
By Joey Roulette
WASHINGTON (Reuters) - The head of NASA is set to announce plans on Friday to name the U.S. space agency's Marshall Space Flight Center in Alabama as headquarters for its human lunar lander programme, signalling progress in its drive to put astronauts back on the moon by 2024, three people familiar with the plan said.
NASA also will designate its Johnson Space Center in Houston to oversee development of a spacecraft to launch astronauts off the moon's surface to a platform in lunar orbit dubbed Gateway, the sources said, speaking on condition of anonymity.
Jim Bridenstine, NASA's administrator, is scheduled to make the announcement at the Marshall facility in Huntsville, the facility from which the lander system, composed of three different parts to be built by a handful of space contractors, will be managed, the sources said.
The two U.S. senators from Texas, Republicans Ted Cruz and John Cornyn, and a Republican U.S. congressman from the state, Brian Babin, urged Bridenstine in a letter on Thursday to reconsider the decision and hold off on making an announcement. The three lawmakers argued that Johnson Space Center should anchor the lunar landing programme instead of the Alabama site.
Marshall Space Flight Center is where the family of rockets used in the Apollo programme that first sent astronauts to the moon a half century ago were built.
Companies including billionaire entrepreneur Jeff Bezos' Blue Origin, Elon Musk's SpaceX and Lockheed Martin Corp
Bridenstine in May named the programme Artemis and asked Congress to increase NASA's proposed budget for fiscal 2020, which begins Oct. 1, by $1.6 billion, the bulk of which would be earmarked to seed commercial development of the human lunar landing system.
"Standing up programme offices is a really, really big deal," one industry source involved with the plans said. "Things start to move quickly, requirements get firmed up, and you get that authority and accountability."
The new lunar mission - an endeavour likely to cost $20 billion to $30 billion dollars over five years - comes as NASA seeks with the help of private partners to resume human space missions from American soil for the first time since its space shuttle programme ended in 2011.NASA announced Bridenstine's scheduled appearance at the Marshall facility without giving details of the announcement. It said Alabama Republican U.S. Representatives Mo Brooks and Robert Aderholt and other lawmakers are due to join Bridenstine, himself a former Republican congressman, on Friday.
Vice President Mike Pence in March announced an accelerated timeline for NASA to put astronauts back the lunar surface by 2024, cutting in half a previous goal to get there by 2028.
President Donald Trump's own support for the mission has been unclear. In June, the Republican president criticized NASA for aiming to put astronauts back on the moon by 2024 and urged the agency to focus instead on "much bigger" initiatives like going to Mars, undercutting his previous support for the lunar initiative.
(Reporting by Joey Roulette; Editing by Bill Tarrant and Will Dunham)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
(Reuters) - Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for Immunomedics, which last month reported positive data from a late-stage study for its breast-cancer drug, could be announced Monday if not sooner, the Journal said https://www.wsj.com/articles/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-11599936777?mod=hp_lead_pos2. Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment
SHANGHAI (Reuters) - China banned pork imports from Germany on Saturday after it confirmed its first case of African swine fever last week, in a move set to hit German producers and push up global prices as China's meat supplies tighten. China's ban on imports from its third largest supplier comes as the world's top meat buyer deals with an unprecedented pork shortage after its own epidemic of the deadly hog disease. The ban on Germany, which has supplied about 14% of China's pork imports so far this year, will push up demand for meat from other major suppliers like the United States and Spain, boosting global prices.
CAIRO (Reuters) - Libyan commander Khalifa Haftar has committed to ending a months-long blockade of oil facilities, the U.S.